DotLab

Executive Summary

DotLab is a women's health diagnostics company developing non-invasive blood tests to improve diagnosis of endometriosis, a condition that affects 1 in 10 women and currently takes an average of 7-10 years to diagnose. Its flagship product, DotEndo, measures specific microRNA biomarkers from a simple blood draw, offering a less invasive alternative to laparoscopy. The company was founded in 2015 and is headquartered in New York. By addressing the significant diagnostic delay and lack of non-invasive tools in endometriosis, DotLab aims to empower women with earlier detection and better management options. The company operates in the underserved women's health diagnostics market, which is gaining increased attention from investors and healthcare providers. While DotLab's stage and funding are not publicly disclosed, its focus on microRNA biomarkers positions it at the forefront of liquid biopsy innovations for gynecological conditions. If successful, DotEndo could become the first blood-based diagnostic for endometriosis, offering a scalable solution for the estimated 176 million women worldwide affected by the disease.

Upcoming Catalysts (preview)

• Q4 2026Publication of pivotal clinical trial data for DotEndo60% success
• Q2 2027FDA submission or breakthrough device designation50% success
• Q3 2026Strategic partnership or distribution agreement with a diagnostic lab70% success